Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
Scientists found genetic variations that could be used to identify women who are most likely to benefit from a certain type of breast cancer prevention drug—and who should avoid it.
In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy—and which should avoid it.
Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.
Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
When women at high risk of breast cancer viewed a customized web-based decision guide about prevention options, they were more likely to make a choice about prevention and to feel comfortable with their choice, a new study finds.
Eli Lilly and Company today announced that data on EVISTA® (raloxifene HCl tablets) therapy for more than three years was published online in Current Medical Research & Opinion.
Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.
According to an international panel of cancer experts, women at high risk of developing breast cancer should be given preventative drugs. The experts write in the Lancet Oncology adding, drugs such as tamoxifen could reduce the chances of developing breast cancer. They suggest that this would be something similar to prescribing statins to patients at risk of heart disease. But tamoxifen has been linked with womb cancer, blood clots and stroke.
Drugs could be used to prevent breast cancer in women at high risk of the disease in the same way that statins are used for heart disease if trials looking at ways of predicting risk are successful, according to an international panel of cancer experts.
In an update to its 2002 recommendation, the U.S. Preventive Services Task Force now recommends that all women ages 65 and older be routinely screened for osteoporosis.
Bionovo, today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth. These results provide evidence that drugs that stimulate the production of or activate ERb are potential new therapies to prevent breast cancer.
Experts have warned that women who have their breasts removed out of fear of a high hereditary risk of breast cancer may be doing so needlessly. Genetic tests like for the BRCA mutations have predicted a high risk of getting breast cancer in women with many breast cancer sufferers among their first degree relatives. Earlier studies suggest the risk of the mutation to predict the cancer 87% of the time. Now experts want that this is an overestimate.
Medtronic Inc. today announced Food and Drug Administration (FDA) clearance of the Kyphon Xpander II Inflatable Bone Tamp (IBT) for the treatment of vertebral compression fractures with minimally invasive Kyphon Balloon Kyphoplasty
Eli Lilly and Company today announced that a total of 14 U.S. and global studies involving its osteoporosis medications, FORTEO® [teriparatide (rDNA origin) injection] and EVISTA® (raloxifene HCl tablets), will be presented at the American Society for Bone and Mineral Research (ASBMR) 2010 Annual Meeting from October 15-19 in Toronto, ON, Canada.
Ligand Pharmaceuticals Incorporated today announced that its partner Pfizer, Inc. launched Viviant® (Bazedoxifene) in Japan for the treatment of postmenopausal osteoporosis. Under the brand name Conbriza®, the drug is also marketed in Spain through a co-promotion with Almirall, an international pharmaceutical company based in Spain.
The osteoporosis drug raloxifene may be useful in treating kidney disease in women, suggests a new study led by Michal Melamed, M.D., M.H.S., assistant professor of medicine and epidemiology & population health at the Albert Einstein College of Medicine of Yeshiva University.
Medtronic Inc. today announced the launch of the new KYPHON® Express™ Curette for scraping or scoring bone in the spine, including during treatment of vertebral compression fractures with minimally invasive KYPHON® Balloon Kyphoplasty.
Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.
Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.
Despite the dramatic results of the Prostate Cancer Prevention Trial (PCPT), which showed a significant reduction in prostate cancer among those taking finasteride, physicians have not increased its use, according to a study published in the September issue of Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.